Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EPHA7
REST API REST API
Homo sapiens
EPHA7 is differentially expressed in 198 experiments: 87 organism parts: lung, bone marrow, ... (85 more);, 100 disease states: normal, prostate carcinoma, ... (98 more);, 55 cell types 261 cell lines 24 compound treatments and 67 other conditions.
Synonyms Hek11
Orthologs EPHA7 (Bos taurus)   Epha7 (Rattus norvegicus)   ENSCING00000003233 (Ciona intestinalis)   F7B2R2_CIOIN (Ciona intestinalis)   ENSCING00000011899 (Ciona intestinalis)   Q4H3M5_CIOIN (Ciona intestinalis)   Q4H3M4_CIOIN (Ciona intestinalis)   Epha7 (Mus musculus)   Eph (Drosophila melanogaster)   epha7 (Danio rerio)   EPHA7_CHICK (Gallus gallus)   epha7 (Xenopus laevis)   EPHA7 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ephrin receptor activity, phosphorylation, negative chemotaxis, protein binding, membrane, postsynaptic membrane, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, ephrin receptor binding, axon guidance receptor activity, positive regulation of apoptosis, regulation of cell-cell adhesion, retinal ganglion cell axon guidance, ATP binding, axon guidance, neuromuscular junction, integral to plasma membrane, dendrite, receptor activity, nucleotide binding, protein serine/threonine kinase activity, brain development, protein kinase activity, neuronal cell body, branching morphogenesis of a nerve, regulation of ERK1 and ERK2 cascade, regulation of peptidyl-tyrosine phosphorylation, ephrin receptor signaling pathway, chemorepellent activity, positive regulation of neuron apoptosis, protein phosphorylation, regulation of protein autophosphorylation, regulation of cysteine-type endopeptidase activity involved in apoptotic process, GPI-linked ephrin receptor activity
InterPro Term SAM, SAM_2, Ephrin_rcpt_lig-bd, Prot_kinase_cat_dom, Tyr-kin_ephrin_A/B_rcpt-like, SAM_type1, Tyr_kinase_ephrin_rcpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom, Fibronectin_type3
UniProt Accession Q15375
Search EB-eye ENSG00000135333
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-GEOD-1563, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, ... (33 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-2509
U87
2
E-MEXP-903, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-20081, E-GEOD-19639
HH
1
E-MTAB-37
CMLT1
1
E-MTAB-37
255 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (29 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18147
embryonic stem cell
1
2
E-MEXP-930, E-MEXP-2426, E-GEOD-26672
spheroid recovery
1
E-GEOD-4219
SCC
1
E-GEOD-19188
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
mononuclear
1
E-GEOD-26672
49 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2549, E-GEOD-9692, E-MTAB-62, ... (38 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MEXP-2034, E-MTAB-37, E-MTAB-62, E-GEOD-7307
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
benign prostatic hyperplasia
1
2
E-MEXP-2034, E-GEOD-7307, E-MEXP-1243
Duchenne muscular dystrophy
1
E-GEOD-3307
hiv infection
1
E-MTAB-62
94 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-1417, E-TABM-782, E-GEOD-6462, ... (15 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-1417, E-GEOD-412, E-TABM-782, E-GEOD-1676, E-MEXP-1958 ... (5 experiments)
neocarzinostatin
1
E-GEOD-1676
Cxcl12
1
1
E-GEOD-7307
mannitol
1
E-GEOD-6400
TNF
1
1
E-GEOD-15205
camptothecin
1
E-GEOD-1417
18 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653

Factor Value U/D Experiments
29
2
1
E-GEOD-3494
44
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-5372, E-GEOD-19246, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-MEXP-563

Genotype
studied in E-MEXP-1437, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-TABM-868, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-20504, E-GEOD-9764, E-MEXP-1741 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-666, E-MEXP-1648, E-GEOD-19519, ... (24 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr ereg dct
studied in E-GEOD-5851

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-3494, E-GEOD-6532

Processing time: 0.368 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM